This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.
We hope you can join us for this online event with Dr. Dan Veljovich of the Swedish Cancer Institute, which aims to highlight the current landscape in the management of patients with ovarian cancer and the treatment advances observed over the last decade.
Upon completion of this activity, participants will be able to:
- Summarize the rationale for maintenance therapy in ovarian cancer.
- Evaluate the efficacy and safety results of available maintenance therapies in ovarian cancer to tailor treatment recommendations.
- Implement individualized strategies to effectively manage and prevent adverse events for ovarian cancer maintenance therapy.
- Utilize genetic biomarker testing for individualized treatment and prevention recommendations for women with or at risk for ovarian cancer.
Note that the time of the meeting is in EST.
REGISTER TODAY! IT'S FREE
Speakers
Dan
Veljovich
Gynecologic Oncologist at Swedish Cancer Institute
Dr. Dan Veljovich was born and raised in Southern California and studied Biochemistry and Cell Biology at UC San Diego before pursuing his medical training on the East Coast where he earned his medical degree and completed a residency in OB/GYN at the University of Virginia and trained in gynecologic oncology as a fellow at the University of North Carolina.
He is a gynecologic oncologist at Swedish Cancer Institute and enjoys training residents and fellows as a gynecologic oncologist at Providence/Swedish Medical Center and is an associate clinical professor in the department of OB/GYN at the University of Washington.
In 2006, he co-initiated the first gynecologic oncology robotic surgery program in the Pacific Northwest and published the first peer-reviewed article in the medical literature evaluating robotic surgery in endometrial cancer. He has been an invited speaker on this topic for the European Society of Gynecologic Oncologists and the Society of Gynecologic Oncologists.
He has been actively involved in accruing patients to clinical trials evaluating novel agents and became interested in PARP inhibitors participating in an institutional Phase IB/II expansion trial of olaparib in 2010 and was involved in clinical trials of bevacizumab and PARP inhibitors prior to FDA approval of these drugs.
A fellow of the American College of Obstetricians and Gynecologists, Dr. Veljovich is a past President of the Seattle Gynecologic Society, has served on the program committees for SGO 2010 and 2020, and has been consistently selected as a “Top Doctor” in gynecologic oncology in Seattle Magazine and Seattle Metropolitan Magazine. In his free time, he enjoys running, snowboarding, hiking, and spending time with his family and dog.
Sponsors and Partners
Organizer
The Society of Gynecologic Oncology of Canada
Our mission is to improve the care of women with or at risk of gynecologic cancer by raising standards of practice, encouraging ongoing research, promoting innovation in prevention, care and discovery, and advancing awareness. GOC also seeks to disseminate knowledge to practitioners, patients and the general public on gynecologic cancer as well as cooperate with other organizations committed to women’s health care, oncology, and related fields.
https://www.gyneoncology.ca
AstraZeneca/Merck
AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.
The company employs roughly 900 people in Canada who work to research, develop and market innovative medicines. AstraZeneca Canada was recently designated a global Clinical Hub for oncology and immuno-oncology clinical studies. We are currently leading global oncology clinical studies in lung, head and neck cancer.
The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus is on the following core therapy areas: Cardiovascular, Renal and Metabolic diseases (CVRM); Oncology; and Respiratory & Immunology.
In 2019, AstraZeneca invested more than $145 million in Canadian health sciences research in our core therapy areas.
AstraZeneca Canada was named one of Canada’s 10 Most Admired Cultures in 2020 by Waterstone Human Capital – a national award that recognizes best-in-class Canadian organizations with a commitment to strong and vibrant corporate cultures anchored to their people and values. The company was also recognized as being one of the top employers in the Greater Toronto Area – the seventh consecutive year AstraZeneca has received a Greater Toronto Top Employer Award. https://www.astrazeneca.ca/en
At Merck Canada, we are inspired by a shared vision and mission to save and improve lives. To make a difference in the lives of people through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future. https://www.merck.ca/en/home/